ArticleJournal of the American Chemical Society2011
Impact of distinct chemical structures for the development of a methamphetamine vaccine.
Article in Journal of the American Chemical Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 79 citations in OpenAlex.
- Nanoparticle-Mediated Brain-Targeted Drug Delivery for Methamphetamine Use Disorder: Advances, Challenges and Translational Perspectives.International journal of nanomedicine · 2026Review
- Precision Adjuvant Strategies in Vaccine Development for Substance Use Disorders: Variability and Mechanistic Insights.Pharmaceutics · 2025Review
- Therapeutic targeting of neuroinflammation in methamphetamine use disorder.Future medicinal chemistry · 2025Review
- Vaccines to Treat Substance Use Disorders: Current Status and Future Directions.Pharmaceutics · 2024Review
- Expedited Evaluation of Conformational Stability-Heterogeneity Associations for Crude Polyclonal Antibodies in Response to Conjugate Vaccines.Analytical chemistry · 2023Article
- Development of Methamphetamine Conjugated Vaccine through Hapten Design: In Vitro and In Vivo Characterization.Vaccines · 2023Article
- Immunotherapeutic strategies for treating opioid use disorder and overdose.Expert opinion on investigational drugs · 2023Review
- Immunotherapies for the Treatment of Drug Addiction.Vaccines · 2022Review
- Article
- Calix[Journal of advanced research · 2022Article
- A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects.ImmunoTargets and therapy · 2022Review
- Family of Structurally Related Bioconjugates Yields Antibodies with Differential Selectivity against Ketamine and 6-Hydroxynorketamine.ACS chemical neuroscience · 2021Article
- Immunopharmacotherapeutic advancements in addressing methamphetamine abuse.RSC chemical biology · 2021Review
- Hapten Design and Monoclonal Antibody to Fluoroacetamide, a Small and Highly Toxic Chemical.Biomolecules · 2020Article
- Emerging Concepts and Technologies in Vaccine Development.Frontiers in immunology · 2020Review
- Psychopharmacology: neuroimmune signaling in psychiatric disease-developing vaccines against abused drugs using toll-like receptor agonists.Psychopharmacology · 2019Review
- Consequence of Hapten Stereochemistry: An Efficacious Methamphetamine Vaccine.Journal of the American Chemical Society · 2019Article
- Novel technologies in detection, treatment and prevention of substance use disorders.Journal of food and drug analysis · 2019Review
- A rapid solution-based method for determining the affinity of heroin hapten-induced antibodies to heroin, its metabolites, and other opioids.Analytical and bioanalytical chemistry · 2018Article
- Ethical Implications in Vaccine Pharmacotherapy for Treatment and Prevention of Drug of Abuse Dependence.Journal of bioethical inquiry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
(+)-Methamphetamine (METH) use and addiction has grown at alarming rates over the past two decades, while no approved pharmacotherapy exists for its treatment. Immunopharmacotherapy has the potential to offer relief through producing highly specific antibodies that prevent drug penetration across the blood-brain barrier thus decreasing reinforcement of the behavior. Current immunotherapy efforts against methamphetamine have focused on a single hapten structure, namely linker attachment at the aromatic ring of the METH molecule. Hapten design is largely responsible for immune recognition, as it affects presentation of the target antigen and thus the quality of the response. In the current paper we report the systematic generation of a series of haptens designed to target the most stable conformations of methamphetamine as determined by molecular modeling. On the basis of our previous studies with nicotine, we show that introduction of strategic molecular constraint is able to maximize immune recognition of the target structure as evidenced by higher antibody affinity. Vaccination of GIX(+) mice with six unique METH immunoconjugates resulted in high antibody titers for three particularly promising formulations (45-108 μg/mL, after the second immunization) and high affinity (82, 130, and 169 nM for MH2, MH6, and MH7 hapten-based vaccines, respectively). These findings represent a unique approach to the design of new vaccines against methamphetamine abuse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.